Indeed, our in vivo study observed that intraprostatic injection of S1P and S1PR1/3 agonists induced experimental BPH, while S1PR1/3 antagonist alleviated testosterone-induced BPH. Here, S1PR1 is linked to benign prostatic hyperplasia.